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Implantable cardioverter-defibrillator (ICD) therapy
represents a cornerstone treatment in patients at risk for
sudden cardiac death.1,2 Indications for ICD therapy have
evolved considerably from survivors of sustained ven-
tricular tachycardia or ventricular fibrillation to patients
with depressed left ventricular (LV) systolic function
(LV ejection fraction (LVEF) \ 30-40%), regardless of
prior ventricular tachyarrhythmias.3-8
The merits of ICD therapy have been demonstrated
in several large randomized trials.3-8 The first Multicenter
Automatic Defibrillator Implantation Trial (MADIT) was
one of the first studies evaluating the effectiveness of
defibrillator therapy on the reduction of arrhythmic death
in patients with depressed LV systolic function.7 The
prospectively designed study evaluated whether prophy-
lactic ICD implantation showed improved survival when
compared to conventional medical therapy alone. Over a
5-year course, 196 patients with a prior myocardial
infarction and depressed LV systolic function (LVEF B
35%) were enrolled and randomly assigned to ICD ther-
apy (n = 95) or medical therapy alone (n = 101). During
a mean follow-up of 27 months, all-cause mortality was
significantly lower in patients with ICD therapy as com-
pared to patients with conventional medication alone
(16% vs 39%, P \ .05). The MADIT I trial has shown
that the use of prophylactic ICD therapy was associated
with a significantly improved survival as compared to
patients on medical therapy (HR 0.46, 95% CI 0.26-0.82,
P \ .01).
Even though the efficacy of ICD therapy have been
demonstrated in several landmark trials,3-8 the risk of
cardiac death remained considerably high in patients
who underwent ICD implantation.9-11 Several random-
ized trials have shown that a substantial number of ICD
recipients died because of progressive heart failure.9-11
The recent randomized clinical Immediate Risk Strati-
fication Improves Survival (IRIS) trial, which was
designed to evaluate the efficacy of early ICD therapy
(within 40 days of myocardial infarction) in patients
with depressed LV systolic function, showed that the
number of ICD recipients who died because of non-
sudden cardiac death was considerably high; more than
15% of the ICD recipients died over a mean follow-up
of 37 months.9 Additionally, post-hoc analysis of the
Sudden Cardiac Death in Heart Failure Trial (SCD-
HeFT) revealed that progressive heart failure contrib-
uted significantly to all-cause mortality in patients with
ICD treatment.11 Progressive heart failure was identified
as the mode of death in 40% of the ICD recipients who
died over a mean follow-up of 45.5 months.11
Cardiac resynchronization therapy (CRT) represents
an effective treatment option in patients with moderate-
to-severe drug-refractory heart failure.12-15 Resynchro-
nization therapy has been shown to improve the inherent
electrical cardiac function by stimulating the ventricles
in a synchronized manner.12-15 The improvement in
cardiac performance, induced by synchronized pacing
(which restores the intrinsic electrical conduction), has
been consistently demonstrated in patients with moder-
ate-to-severe heart failure (NYHA functional class III or
IV) and ventricular conduction delay.12-15 The Com-
parison of Medical Therapy, Pacing and Defibrillation in
Heart Failure (COMPANION) trial demonstrated that
resynchronization therapy resulted in a 19% risk
reduction of the primary endpoint (time to death from or
hospitalization for any cause) as compared to optimal
medical therapy alone in 1520 patients with NYHA
functional class III or IV heart failure (HR 0.81,
P = .014).14 Additionally, a recent post-hoc analysis of
the COMPANION trial was published evaluating the
effect of CRT on the number of hospitalizations during
follow-up.15 In this study, resynchronization therapy
was associated with a 44% reduction of heart failure
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hospital admissions and a 21% reduction of all-cause
hospitalizations per patient-year of follow-up.
Recently, the hypothesis that resynchronization
therapy may delay or interrupt the progressive decline in
cardiac function in patients with mild heart failure, as
indicated by NYHA functional class I or II, was evaluated
in the Resynchronization Reverses Remodeling in Sys-
tolic Left Ventricular Dysfunction (REVERSE) trial.16
St. John Sutton et al16 sought to determine whether
patients with NYHA I-II heart failure showed favorable
effects on LV geometry and function with resynchroni-
zation therapy. In total, 610 patients with mild heart
failure (NYHA functional class I-II), depressed LV sys-
tolic function (LVEF B 40%), prolonged QRS interval
(C120 ms) and LV end-diastolic dimension (C55 mm)
were included. Randomization of patients was performed
according to a 2:1 model; 419 patients received resyn-
chronization therapy (on top of optimal medical
treatment) and 191 patients received optimal medical
therapy alone during 12 months of follow-up. Patients
with CRT showed considerable reverse remodeling (as
reflected by a significant decrease in LVESV and
LVEDV index) as compared to patients without CRT
during 12 months. Moreover, LV systolic function
improved significantly in patients with resynchronization
therapy (27.2% ± 6.6% vs 31.8% ± 8.8%, P \ .01),
whereas no significant improvement was observed in
patients without resynchronization therapy. Thus, favor-
able effects on LV structure and function were observed
in patients with mild heart failure and resynchronization
therapy. Moreover, the authors postulated that the pro-
gressive deterioration of cardiac function in patients
with mild heart failure may be delayed or interrupted by
resynchronization therapy, and probably this may lead to
a change in the natural course of the disease.
Additionally, the value of resynchronization therapy
in patients with mild heart failure and depressed LV
systolic function was addressed by the Multicenter
Automatic Defibrillator Implantation Trial with Cardiac
Resynchronization Therapy (MADIT-CRT) trial.17 A
total of 1820 patients with mild heart failure symptoms
and depressed LV systolic function (LVEF B 30%)
were included. During a mean follow-up of 2.4 years,
the primary endpoint (defined as all-cause mortality or
nonfatal heart failure events) was significantly less often
documented in patients receiving CRT-D when com-
pared to patients receiving ICD treatment alone (17.2%
vs 25.3%, P \ .01). More specifically, a risk reduction
of 34% for primary endpoint events was observed for
patients receiving CRT-D (HR 0.66, 95% CI 0.52-0.84,
P \ .01), as compared with those in the ICD group.
These positive effects of CRT-D were primarily driven
by a 41% risk reduction of the risk for nonfatal heart
failure events (HR 0.59, 95% CI 0.47-0.74, P \ .01).
Despite its beneficial effects, the efficacy of resyn-
chronization therapy has not been demonstrated in all
patients currently indicated for CRT.18-20 It has been
demonstrated that a substantial group of patients (30-
40%), who were selected according to current criteria on
CRT, did not show significant improvement in heart
failure symptoms or LV systolic performance.21,22 LV
dyssynchrony may play an important role as it has been
identified as an important predictor of response to
CRT.21,22 Multiple clinical studies have shown that pre-
existent LV dyssynchrony predicts response to CRT in
patients with symptomatic advanced heart failure
despite optimal pharmacologic treatment.21,23-25 Acute
hemodynamic improvement after CRT has been related
to LV dyssynchrony at baseline.23,25,26 Breithardt et al26
sought to determine whether pre-existent LV dyssyn-
chrony predicts acute response to CRT in 34 patients
with heart failure. LV dyssynchrony was evaluated using
echocardiographic phase analysis of LV septal and lat-
eral wall motion and the absolute difference in septal
and lateral wall motion phase angle (DLS) was used as
an indicator of LV dyssynchrony. Accordingly, patients
were stratified into patients with or without LV dys-
synchrony. In all patients, acute hemodynamic response
to CRT was expressed in percentage increase in dP/
dtmax. Patients with baseline LV dyssynchrony showed
significantly larger increase in dP/dtmax with CRT as
compared to patients without LV dyssynchrony
(26% ± 14% vs 2% ± 1%, P \ .05) at baseline.
Accordingly, the study demonstrated that LV dyssyn-
chrony could be used for identification of patients who
showed acute response to CRT.
Additionally, the value of LV dyssynchrony has
been demonstrated in studies evaluating the long-term
effects of CRT.27,28 Sogaard et al27 evaluated whether
baseline LV dyssynchrony could predict the long-term
effects of CRT. Twenty-five consecutive patients with
advanced heart failure and left-bundle branch block
configuration were enrolled. The study demonstrated
that the extent of baseline LV dyssynchrony (as assessed
with 3D echocardiography and tissue Doppler imaging)
was predictive for long-term response to CRT. Recently,
the prospective study performed by Soliman et al28
sought to determine the role of LV dyssynchrony as
assessed with 3D echocardiography for prediction of
long-term response to CRT. The patient population
consisted of 90 patients who were referred for CRT
because of severe drug-resistant heart failure. All
patients underwent echocardiographic evaluation before
and 12 months after CRT. The standard deviation of
time to minimum systolic volume of the 16 LV seg-
ments was used to define the systolic dyssynchrony
index (SDI). CRT response was defined as a [15%
decrease in LV end-systolic volume. A SDI [10%
Journal of Nuclear Cardiology Boogers et al 355
Volume 17, Number 3;354–8 Should mechanical dyssynchrony be assessed?
yielded a sensitivity of 96% and a specificity of 88% for
prediction of long-term response to CRT.
Thus, LV dyssynchrony may aid to identify poten-
tial responders to resynchronization therapy. Currently,
the majority of studies have focused on echocardio-
graphic techniques to evaluate the extent of LV
dyssynchrony.21,23-26 Despite its potentials, one of the
major drawbacks of echocardiographic assessment of
LV dyssynchrony remains its high intra- and interob-
server variability; an issue that has been addressed in the
Predictors of Response to Cardiac Resynchronization
Therapy (PROSPECT) trial.29 As a consequence, the
results of the PROSPECT trial have prompted the search
for improved techniques to assess LV dyssynchrony.
Phase analysis on gated myocardial perfusion single
photon emission computed tomography (SPECT) has
emerged as an interesting technique that provides
information on cardiac wall motion in addition to the
evaluation of myocardial infarction and ischemia.30,31
Currently, several nuclear studies using phase analysis
on gated myocardial perfusion SPECT have demon-
strated that LV dyssynchrony provides useful
information in patients with CRT.32,33 Henneman et al33
evaluated whether phase analysis on gated myocardial
perfusion SPECT was able to predict response to CRT at
6 months in 42 patients with advanced heart failure. An
improvement of C1 New York Heart Association
(NYHA) functional class was used as a criterion for
CRT response. The extent of LV dyssynchrony was
significantly larger in responders as compared to non-
responders to CRT, as reflected by higher values of
histogram bandwidth (175 ± 63 vs 117 ± 51, P \ .01)
and phase standard deviation (56.3 ± 19.9 vs
37 ± 14.4, P \ .01) in responders to CRT. Further-
more, ROC curve analysis was performed to identify the
optimal point for prediction of response to CRT. A
cutoff point of 135 for histogram bandwidth yielded a
sensitivity and specificity of 70% for prediction of
response to CRT. For phase standard deviation, a cutoff
point of 43 yielded a sensitivity and specificity of 74%
for prediction of CRT response. As a result, this study
demonstrated that LV dyssynchrony derived from phase
analysis on gated myocardial perfusion SPECT could be
used to identify responders to CRT.
Accordingly, the question comes up whether LV
dyssynchrony can also be used to identify patients with
ICD therapy who will show additional benefit from
receiving combined resynchronization-defibrillator
therapy. Even though this was not tested in the study by
Aijaroudi et al,34 the study clearly demonstrated that LV
dyssynchrony was associated with increased risk of
adverse cardiovascular events in ICD recipients. The
retrospective study by Aijaroudi et al34 was based on 70
patients with depressed LV systolic function (LVEF \
40%) and ICD therapy. For comparison reasons, 157
control patients with normal LV systolic function were
enrolled. Stress-rest gated myocardial perfusion SPECT
imaging was performed in all patients within 6 weeks
prior to ICD implantation. Automated phase analysis
was applied to the conventional gated SPECT data sets
to evaluate the extent of baseline LV dyssynchrony, as
reflected by the histogram bandwidth and phase standard
deviation. Furthermore, all-cause mortality and appro-
priate ICD shocks (both were used as the primary
endpoint) were identified in all patients during clinical
follow-up. All-cause mortality or appropriate ICD shock
was identified in 8 (11%) patients at 1-year follow-up.
ICD patients showed significantly more LV dyssyn-
chrony as compared to the healthy control patients.
In addition, phase standard deviation (60 ± 5 vs
50 ± 21, P \ .01) was significantly higher in patients
with an event as compared to patients without an event
during follow-up, and the histogram bandwidth
(185 ± 37 vs 154 ± 75, P = .07) tended to be higher
in patients with an event as compared to patients without
an event. Moreover, a phase standard deviation of\50
was associated with no events during follow-up.
Importantly, the study suggests that patients with
extensive LV dyssynchrony have an increased risk for
cardiac death partially due to progressive heart failure.
Although the current study provides important
information for prognostication of ICD patients, some
limitations need to be considered. The association
between baseline LV dyssynchrony and cardiovascular
events was evaluated in a small subset of patients using a
retrospective approach. A prospective analysis would
have been preferred when evaluating the predictive value
of LV dyssynchrony in ICD patients. Furthermore, the
current findings are based on a small number of adverse
events. In total, only 8 patients (3 patients died and 5
patients received appropriate ICD shock) showed an event
at 1-year follow-up. Moreover, a combined endpoint
(consisting of all-cause mortality and appropriate ICD
shocks) was used to evaluate the predictive value of
baseline LV dyssynchrony in ICD recipients. However, a
single endpoint (cardiac death due to progressive heart
failure) would have been preferred to assess the predictive
value of baseline LV dyssynchrony in ICD patients.
Additional prospective studies are needed that
evaluate whether LV dyssynchrony can be used to select
patients who should receive combined resynchroniza-
tion-defibrillator therapy or defibrillator therapy alone.
These prospective studies should stratify patients, who
are currently indicated for ICD therapy, according to the
presence of baseline LV dyssynchrony into patients with
or without LV dyssynchrony; patients with baseline LV
dyssynchrony should receive combined resynchroniza-
tion-defibrillator therapy, whereas patients without
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baseline LV dyssynchrony should receive defibrillator
therapy alone. These prospectively designed studies will
establish the actual role of LV dyssynchrony in patients
currently indicated for ICD therapy.
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